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1Department of Chemistry, University of Cambridge, Cambridge, United KingdomABSTRACT Increasingly prevalent neurodegenerative diseases are associated with the formation of nanoscale amyloid ag-
gregates from normally soluble peptides and proteins. A widely used strategy for following the aggregation process and defining
its kinetics involves the use of extrinsic dyes that undergo a spectral shift when bound to b-sheet-rich aggregates. An attractive
route to carry out such studies is to perform ex situ assays, where the dye molecules are not present in the reaction mixture, but
instead are only introduced into aliquots taken from the reaction at regular time intervals to avoid the possibility that the dye mol-
ecules interfere with the aggregation process. However, such ex situ measurements are time-consuming to perform, require
large sample volumes, and do not provide for real-time observation of aggregation phenomena. To overcome these limitations,
here we have designed and fabricated microfluidic devices that offer continuous and automated real-time ex situ tracking of the
protein aggregation process. This device allows us to improve the time resolution of ex situ aggregation assays relative to con-
ventional assays by more than one order of magnitude. The availability of an automated system for tracking the progress of pro-
tein aggregation reactions without the presence of marker molecules in the reaction mixtures opens up the possibility of routine
noninvasive study of protein aggregation phenomena.INTRODUCTIONThe importance of folding polypeptide chains into three-
dimensional structures has been recognized across a num-
ber of fields, such as medicine, food processing, material
science, and nanotechnology (1–7). In particular, protein
misfolding, the subsequent amyloid formation, and the
eventual buildup of fibrillar deposits, has been brought
into connection with the onset of a wide range of neurode-
generative and other disorders, such as Alzheimer’s,
Parkinson’s disease, and type-II diabetes (8–14). Despite
the well-established connection between protein aggrega-
tion and neurodegenerative disorders, the molecular
mechanisms that underlie this process have been chal-
lenging to establish. This difficulty has in part originated
from the challenges associated with performing reliable
assays of this process in vitro. One of the most frequently
employed techniques for monitoring of aggregation in-
volves the use of extrinsic amyloidophilic probes. Upon
binding to b-sheet-rich fibrils, such dyes exhibit changes
in their fluorescent spectra that can be recorded externally
with a spectrophotometer, and hence allow the b-sheet-
rich amyloid aggregates to be detected and their amount
to be quantified (15).Submitted July 21, 2015, and accepted for publication November 25, 2015.
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0006-3495/16/02/0555/6Yet many of the frequently used probes, such as Congo
Red or thioflavin S, have a propensity to influence protein
misfolding and aggregation processes and do not permit reli-
able extraction of quantitative information on the concentra-
tion of aggregated material present (15–17). Indeed, some
very effective b-breaker molecules that inhibit protein ag-
gregation have structures that are modeled on amyloido-
philic dyes (18–21). Other probes, such as thioflavin T
(ThT), have been suggested not to exhibit any or exhibit
only minimal interference with the aggregation process
(16,17). However, the exact mechanism of their binding
to fibrils is still unclear (17,21,22) and conventional in situ
assays (Fig. 1 a I) where the marker molecules are present
throughout the reaction, commonly yield signals which,
as shown in this work (Fig. 1 b, circles) as well as by others
(23,24), are not directly proportional to the concentration
of aggregates and are hence challenging to interpret in a
quantitative manner. Moreover, the fluorescence properties
of ThT, especially its quantum yield, are affected by
extrinsic conditions (15), and because the fluorescence
readout takes place directly within the reaction environment,
the measured signal is highly dependent on the surrounding
environment—making comparison between different exper-
imental conditions challenging (Fig. 1 c, circles).
These problems can be effectively eliminated through the
use of an ex situ measurement strategy (Fig. 1 a II), where
the probe molecules are not brought into contact with the re-
action mixture but instead with aliquots taken from the ag-
gregation sample, thus avoiding any interaction between the
aggregating protein and the dye. In addition to allowinghttp://dx.doi.org/10.1016/j.bpj.2015.11.3523
ab
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FIGURE 1 Advantages of ex situ over in situ aggregation assays. (a) In
situ assays (I) are straightforward to follow but they require direct introduc-
tion of probe molecules into the aggregation assay. Interference of the ag-
gregation process by probe molecules can be avoided in ex situ assays (II),
where small samples of an aggregating protein solution are extracted and
diluted at specified time points into a buffered solution containing an appro-
priate dye molecule. But conventional ex situ assays are labor-intensive and
may perturb the aggregation mixture. (b) Fluorescence intensity of the ag-
gregation end-point in ex situ (blue triangles; R2 ¼ 0.997) and in situ (red
circles) assays at different concentrations of insulin in the same aggregation
environment (50 mM NaCl, pH 2.0) recorded on a microplate reader. (c)
When diluting ex situ assays, performed at varying salt concentrations
into a set measurement solution (500 mM NaCl) containing the probe
molecules, any effect of the aggregation solution can be eliminated (blue
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concentration of aggregates (Fig. 1 b, triangles) and hence
quantitative interpretation of the latter, the reaction and
measurement steps are spatially separated and chemically
decoupled, making comparison between aggregation reac-
tions that take place in different environmental conditions
(e.g., buffer) possible (Fig. 1 c, triangles).
Despite their advantages, conventional ex situ measure-
ments (Fig. 1 a II) possess some drawbacks that have limited
their widespread adoption: they are laborious to perform, as
every time point requires manual intervention; and the reac-
tion can be followed only at a limited number of time points.
Furthermore, the requirement to physically separate aliquots
from the reaction mixture implies the use of large physical
volumes for the aggregating protein solution. Last but not
least, withdrawing aliquots often results in agitation of the re-
action mixture and can have a significant effect on aggrega-
tion if the process is to be studied under quiescent conditions.
Here we address the limitations of conventional ex situ as-
says by designing and fabricating microfluidic devices that
automate themanual aliquot-taking process required for con-
ventional ex situ measurements, eliminate the need to phys-
ically separate aliquots from the reaction mixture, and allow
themonitoring of protein aggregation in real-time. This strat-
egy not only decouples the aggregation process and the mea-
surement spatially to remove any interference between the
aggregation process and the probe, it also ensures that the re-
action time between the dye and the aggregate species is
tightly controlled and kept constant. We show that the strat-
egy underlies a significant improvement in terms of data
throughput compared to manual ex situ assays and allows
hundreds of individual measurements to be performed in
real-time on a single aggregating protein system.MATERIALS AND METHODS
Fabrication of microfluidic devices
Single-layer (SL) microfluidic devices were fabricated in PDMS (poly(di-
methylsiloxane); Dow Corning, Midland, MI) through single, standard
soft-lithography steps using SU-8 3050 photoresist on a polished silicon
wafer (25,26). The channels were sealed with a microscope glass slide after
the surface had been activated with oxygen plasma.
Multilayer (ML) deviceswere generated by plasma-bonding two individual
PDMS chips to each other (27). One of the PDMS chips was prepared in a
manner analogous to the single-layer devices described above, while the other
involved two subsequentUV lithography steps performedwith SU-8 3025 and
3050, respectively. The side channels containing the dye aswell as the channel
of the mixing and labeling area (Fig. 2 a) were fabricated onto bothmicroflui-
dic chips so that they spanned across the height of the device. The protein
channel, however, was fabricated only in the second lithography step of the
double-layer chip so that it would form the middle layer of the 1þ2 layers.
To achieve an alignment accuracy of the order of micrometers, the two
plasma-activated chips were coated in methanol and placed on top of onetriangles); in the in situ assays, the conditions of the aggregation solution
affect the recorded fluorescence values (red circles). All measurements
are the average of n ¼ 3 repeats. To see this figure in color, go online.
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FIGURE 2 (a) Architecture of the SL microfluidic device used in this work. The device has two inlets, one for the solution containing the probe (dye mole-
cule), and the other for the sample solution (contains the aggregating protein).When the streams converge, the dye can start to diffuse into the protein streamand
hence bind the aggregating protein that becomes labeled (yellow). The fluorescence intensity is recorded further downstreamwhere the diffusion of the dye into
the protein stream has resulted in complete binding. (b) A fluorescence microscopy image of the measurement area. (c) Seeded ex situ aggregation curves ob-
tained at 0.03 mg mL1 (blue triangles) and 0.05 mg mL1 (red circles) of bovine insulin using the device in (a) together with manually performed control
assays at the same concentrations (yellow squares and yellow circles, respectively; average of n ¼ 3 repeats). To see this figure in color, go online.
Automated Ex Situ Aggregation Assays 557another, allowing for adjustment in their relative positions under a stereo-
microscope (4.5 magnification). The aligned chips were then placed in
an oven at 65C for 1 h to allow evaporation of the methanol and the cova-
lent bonding to take place. Alignment between these lithography processes
was achieved through a custom-built mask aligner including an x,y,z and a
rotating stage (cat. nos. MBT602/M and PR01/M; ThorLabs, Newton, NJ).Fibril formation assays in microplates
All aggregation assays involved bovine insulin (cat. no. GEM-700-112-P,
used without further purification; Sera Laboratories, Haywards Heath,
West Sussex, UK) in a specified concentration of NaCl at pH 2.0 (adjusted
with HCl). To accelerate the aggregation process, 5% of the initial insulin
was added in the form of preformed seeded fibrils, and the rest of the protein
was in its monomeric form. The preformed fibrils were generated by incu-
bating 10 mg mL1 insulin (pH 2, no NaCl) for 24 h at 60C with maximum
stirring. Before adding the seeds to the aggregation mixture, they were son-
icated (3 times for 5 min, cat. no. HD2070, 8 W, VS 70 probe; Bandelin
Sonopuls, Berlin, Germany) to fragment the fibrils and hence to increase
the number of free ends available for aggregation (28). ThT (final concen-
tration of 30 mM) was added to the aggregation assay either at the start of
the aggregation process (in situ assays) or right before the fluorescence
reading was taken (ex situ assays). In both cases the fluorescence intensities
were recorded on a microplate reader (FLUOstar; BMG LabTech, Thermo
Fisher Scientific, Waltham, MA) at 30C using 96-well, half-area black bot-
tom polystyrene plates (product no. 3881; Corning Life Sciences, Tewks-
bury, MA) with a 100 mL sample in each well. The multiwell plate was
sealed with an aluminum sealing tape (product no. 6570; Corning Life Sci-
ences) to reduce any evaporation of the fluid from the wells.
Manual ex situ assays involved forming a number of separate aliquots of
the aggregation assay to be studied. ThT (final concentration of 30 mM) was
added at different time points during the aggregation process, with the fluo-
rescence intensity recorded on a microplate reader as described earlier, right
after the ThT solution had been introduced.
To examine the effect of the aggregation medium on the resulting fluores-
cence intensity, 0.5 mg mL1 bovine insulin was set to aggregate with (in
situ) and without (ex situ) the addition of ThT in solutions of various ionic
strengths (20–300 mMNaCl) until the aggregation had reached completion.
The ex situ assays were then diluted into a set ThT solution for measure-ment to permit comparison between the protein concentrations. A 1:10 dilu-
tion into a ThT solution of 500 mMNaCl (pH 2) was chosen for the salt that
was present in the original aggregation solution so as not to affect the re-
corded values.Measurements in microfluidic devices
The solution of insulin under the aggregation conditions of interest was in-
jected into the microfluidic device at a flow rate of 50 mL h1 for SL devices
and 5 mL h1 for ML devices. Syringe pumps (neMESYS modules; Cetoni,
Korbussen, Germany) were used to control the flow. ThT (30 mM) was in-
jected from the other inlet (Fig. 2 a) at a flow rate of 200 mL h1 or 20 mL
h1 for the SL or ML devices, respectively. The ThT solution was prepared
in the same solution (50 mM NaCl at pH 2.0) as the aggregation mixture.
The fluorescent signal was recorded (Axio Observer D1 inverted micro-
scope; Carl Zeiss, Jena, Germany and Evolve 512 EMCCD camera; Photo-
Metrics, Huntington Beach, CA) at a fixed point (Fig. 2 a) in the mixing and
labeling area (marked in yellow) using a 440/480 nm filter (excitation and
emission wavelengths) at an exposure time of 5 s. The point chosen was suf-
ficiently downstream for the dye to have diffused into the protein stream
(seconds; Fig. 2 b; see the Supporting Material). Data points were collected
every 1 min over a 10 h period, by the end of which the aggregation reaction
had approached completion. The fluorescence intensity at each data point
was calculated as the difference between the fluorescence intensity of the
ThT bound to the aggregates in the center of the microfluidic channel
and that of the unbound ThT at the edges of the channel (Fig. S3).RESULTS AND DISCUSSION
Microplate reader assays
We first evaluated the performance of in situ and ex situ as-
says for the same protein aggregation reaction in bulk-scale
experiments. To this effect, a series of different concentra-
tions of insulin was left to aggregate for 12 h after seeding
as described in Materials and Methods. The values of the
fluorescence intensity for both in situ and ex situ assaysBiophysical Journal 110(3) 555–560
558 Saar et al.were recorded and are shown in Fig. 1 b. Ex situ assays
exhibit linear scaling of the end-point fluorescence intensity
values with insulin concentration across the range of con-
centrations studied (blue triangles); by contrast, for in situ
assays, a simple linear scaling was not observed in the
same aggregation solutions (red circles). The lack of a sim-
ple relationship between the fluorescence intensity and the
concentration of aggregated protein in the in situ assays is
a general trend, as we demonstrated under a variety of con-
ditions (Fig. S2), with similar trends being observed for
other systems (23,24).
We further followed in situ aggregation of a preset con-
centration of insulin (0.5 mg mL1) in aggregation solutions
of varying the NaCl concentration; the presence of salt had a
marked effect on the observed signal in the in situ assays
(Fig. 1 c, red circles), making a connection between the
observed fluorescence and the concentration of aggregated
protein challenging to establish. By contrast, in the ex situ
assay, the presence of salt did not affect the reading because
the measurement was always taken at set conditions (Fig. 1
c, blue triangles).Microfluidic ex situ measurements
The data in Fig. 1, b and c, highlight the robustness of ex situ
assays under varying solution conditions. However, the
use of such methods by a conventional laboratory is slow,
labor-intensive, and requires large volumes of the aggre-
gating protein mixture to allow for a number of aliquots
with macroscopic volumes to be extracted. Furthermore,
such ex situ measurements perturb the aggregating sample,
making it virtually impossible to reliably analyze aggrega-
tion processes if quiescent conditions are required.
We thus set out to develop a microfluidic platform to
automate ex situ measurements, retaining all of its advan-
tages—most notably the spatial separation and chemical de-
coupling of reaction and measurement—while also offering
the additional benefits of eliminating the need for manual
aliquot taking, allowing tight control over the reaction
time of the dye with the aggregate species, avoiding agita-
tion of the aggregation mixture, and providing the capability
to follow the process in real-time on a single chip. The
objective was achieved by continuous transfer of a label-
free aggregating protein sample to a measurement system
containing buffered dye, with the labeling step occurring
only immediately before the measurement is taken (Fig. 2
a). The fluid moved through the mixing and labeling zone
(marked yellow) in a few seconds—a timescale that is
very short compared to that of the studied aggregation pro-
cess. Hence, effectively no further aggregation occurred in
the presence of the probe molecules.
Aggregation curves obtained for 0.03 mg mL1 (blue tri-
angles) and 0.05 mg mL1 (red circles) insulin assays are
shown in Fig. 2 c (recorded at a time resolution of 60 s).
The fluorescence signal, at long times when aggregationBiophysical Journal 110(3) 555–560had reached completion, can be seen to be proportional
to the initial monomer concentrations, as expected for ex
situ measurement (113 5 6 AU and 192 5 11 AU for
0.03 mg mL1 and 0.05 mg mL1, respectively; average
of n ¼ 30 final values). The observed two-level fluctuations
in the data are likely to have arisen from pulsation of the
flow. The aggregation curves obtained in the microfluidic
devices agree with the ex situ aggregation curves obtained
manually but with a throughput that is increased by approx-
imately two orders of magnitude.
Over 12 h, this single-layer design architecture was found
to yield reliable results up to protein concentrations of
~0.05 mg mL1. For higher concentrations, adhesion was
observed (Fig. S4). To follow the aggregation process accu-
rately at higher concentrations, a multilayer (ML) device
(Fig. 3 b, inset) was designed and built (see Materials and
Methods) that allowed the sample aliquot stream to be
flanked by co-flowing labeling solution in all directions,
thus preventing direct contact between the protein and the
walls of the microfluidic channel where adhesion could
otherwise occur.
Using such a ML device, a seeded aggregation curve, at
an insulin concentration of 0.2 mg mL1, was obtained
(Fig. 3 a), serving to illustrate that the device opens up the
possibility to study aggregation at higher concentrations of
protein. As for the lower concentrations, the data agree
with manually performed ex situ assays where ThT mole-
cules were introduced into separate aliquots at various
time points just before the measurement was taken. In
Fig. 3 b, the three aggregation curves obtained (0.03 mg
mL1 and 0.05 mg mL1 for SL, and 0.2 mg mL1 for a
ML device) are normalized with respect to the intensity at
long times (the average of n¼ 30 final values); all the curves
can be seen to exhibit an absence of lag phase and to
collapse to a good approximation onto a master curve, as ex-
pected for first-order kinetics observed under fully seeded
conditions (29,30).
These microfluidic devices have a number of major advan-
tages over conventional methods of following protein aggre-
gation reaction. Most importantly, spatial separation ensures
that the aggregation reaction is decoupled from the measure-
ment process, hence eliminating the type of interference be-
tween the probe and the aggregating protein that is
encountered in the in situ assays. In addition to providing
such spatial separation between the two processes, the de-
vices allow the aggregation reaction and the measurement
step to be performed in chemically different environments.
Thus, for example, a different buffer, such as onewith higher
ionic strength, could be used to prepare the ThT solution to
amplify the fluorescence signal (31) but leaving the environ-
ment of the aggregation unaffected; the latter process could
still take place in a bufferwith a lower ionic strength. Further-
more, comparison between aggregation reactions happening
in different environments is possible using a set ThT solution,
as illustrated in Fig. 1 c (triangles).
FIGURE 3 (a) Higher-concentration (0.2 mgmL1 insulin) seeded ex situ aggregation curve, obtainedwith theML device, together with manual assays (yel-
low squares, average ofn¼ 3 repeats). (b) The three curves (two lower protein concentrations (0.03mgmL1, blue triangles and0.05mgmL1, red circles) in the
SL device, the highest concentration (0.2 mg mL1, green squares) in the ML device) normalized with respect to the average of the n¼ 30 final values. (Inset)
Mean5 SE image of the cross section of the ML device at the point where the sample and the dye first converge. To see this figure in color, go online.
Automated Ex Situ Aggregation Assays 559Next, the acquisition of ~600 data points over a time period
of 10 h is more than an order-of-magnitude improvement
over manually performed ex situ measurements of protein
aggregation where the time resolution is usually of the order
of tens of minutes, as defined by the normal aliquoting of a
reaction cycle (32–35). The process of transferring the pro-
tein sample into the measurement system is continuous; fluid
handling is no longer the limitation of the achieved time res-
olution. Instead, it is the detection system that determines the
frequency ofmeasurements. The outlined strategy also opens
the possibility to study processes that exhibit fast kinetics and
can be challenging to be followed by manual aliquot taking.
A further key feature of these assays is that the small scale
of microfluidic devices combined with the lack of the
requirement to physically separate macroscopic aliquots en-
ables only miniature volumes of protein solution to be used.
More specifically, the SL device consumed ~500 mL of pro-
tein sample to obtain the full ex situ aggregation curve. As
the high protein flow rate is a necessary requirement to elim-
inate adhering of protein fibrils to the PDMS walls, this
design is best suited for experiments that are less sensitive
toward sample consumption. The ML device, however, is
not restricted to the use of specific flow rates, because any
interaction between the PDMS walls of the device and the
protein is eliminated due to three-dimensional flow. In this
work, ~75 mL of protein sample (includes 25 mL of dead
volume connecting the syringe to the microfluidic device;
this could be reduced further) was sufficient to acquire the
full ex situ aggregation curve (600 data points over 10 h;
120 nL of sample per measurement point). The flow rate
can be decreased further until the precision of the syringe
pumps is reached. Which of the two types of devices is
more appropriate for a particular experiment is a compro-
mise between a multistep fabrication technique and the
amount of protein sample consumed.In addition to this, if following the aggregation process
at high time resolution or continuously is not of relevance,
the syringe pump could be operated under a flow ramp
with the protein sample ejected only at the time when a
measurement is to be taken or control valves could be
added to the design (36,37), thus further reducing protein
consumption. This could be particularly relevant for non-
seeded aggregation assays where high time resolution is
less beneficial during some stage of the process than it is
for others. This approach is applicable to both SL and
ML devices.
It is worth noting that, unlike conventional ex situ assays,
this microfluidic setup does not rely on user interactions to
physically extract aliquots from the aggregation mixture,
thus reducing the risk of perturbing the sample and affecting
the aggregation process. This is especially of import if fully
quiescent aggregation conditions are required. We note that
agitation could be introduced with small-scale magnetic
stirring.
Last but not least, the design strategy that this device uses
can be extended to other types of measurement strategies
where interference with probe is not desirable.CONCLUSIONS
Conventional ex situ measurements yield high-quality data,
but are labor-intensive to perform; they can disturb the reac-
tion mixture and allow reactions to be monitored only at
limited numbers of time points, rather than continuously.
To address those limitations, we have developed high
throughput microfluidic devices that eliminate fluid aliquot-
ing as the limiting factor of the time resolution of ex situ as-
says and instead allow continuous real-time automated
measurements of such assays. Such devices open up the pos-
sibility of extension to other measurement systems, whereBiophysical Journal 110(3) 555–560
560 Saar et al.interference with a probe used to monitor a reaction must be
avoided.SUPPORTING MATERIAL
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